	2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS	12M IR
Total Revenue	26.23	29.11	28.69	29.90	31.13	33.96	38.02	38.43	40.55	32.37	38.91	47.04	48.21	49.56	53.71	57.25
Cost of Operating Revenue	17.29	17.78	16.89	19.95	18.93	19.89	20.85	20.52	20.94	17.52	20.78	24.97	26.66	27.91	31.32	33.47
Gross Profit	8.94	11.33	11.80	9.95	12.21	14.07	17.17	17.91	19.62	14.85	18.13	22.08	21.55	21.65	22.40	23.78
Gross Margin	34.1	38.9	41.1	33.3	39.2	41.4	45.2	46.6	48.4	45.9	46.6	46.9	44.7	43.7	41.7	41.5
Total Operating Expenses	28.21	28.76	28.44	32.50	31.65	34.18	37.17	38.15	39.23	31.14	35.55	42.44	45.41	49.14	54.08	56.97
Operating Profit	-1.98	0.35	0.25	-2.61	-0.52	-0.22	0.85	0.28	1.32	1.23	3.36	4.61	2.80	0.43	-0.37	0.29
Operating Margin	-7.6	1.2	0.9	-8.7	-1.7	-0.6	2.2	0.7	3.3	3.8	8.6	9.8	5.8	0.9	-0.7	0.5
Financing Income/(Expense) - Net	0.06	0.19	0.26	-0.06	-0.08	-0.06	-0.05	-0.06	-0.07	-0.06	-0.13	-0.10	0.40	0.00	-0.86	-1.25
Profit before Taxes	-2.25	0.45	0.10	-2.22	-0.02	0.40	1.70	0.63	1.46	1.99	4.09	5.65	4.01	1.38	-0.05	0.23
Income Taxes	0.01	0.04	0.06	-0.24	-0.12	-0.03	-0.04	-0.08	0.39	0.42	1.11	1.57	1.10	0.64	-0.13	0.08
Profit after Tax	-2.25	0.42	0.04	-1.98	0.10	0.43	1.75	0.71	1.06	1.57	2.98	4.08	2.91	0.74	0.08	0.15
PAT Margin	-8.6	1.4	0.1	-6.6	0.3	1.3	4.6	1.8	2.6	4.8	7.7	8.7	6.0	1.5	0.1	0.3
EPS - Basic - ex Extraordinary Items	-1.08	0.20	0.02	-0.95	0.05	0.21	0.84	0.34	0.51	0.75	1.44	1.96	1.40	0.36	0.04	0.08
EPS - Diluted - ex Extraordinary Items	-1.08	0.20	0.02	-0.95	0.05	0.21	0.84	0.34	0.51	0.75	1.44	1.96	1.40	0.36	0.04	0.08
EBIT	-1.98	0.35	0.25	-2.61	-0.52	-0.22	0.85	0.28	1.32	1.23	3.36	4.61	2.80	0.43	-0.37	0.29
EBITDA	2.02	4.05	3.76	2.16	3.92	3.23	4.22	3.07	3.81	3.56	5.86	7.59	6.53	3.43	3.38	4.85
EBITDA Margin	7.7	13.9	13.1	7.2	12.6	9.5	11.1	8.0	9.4	11.0	15.1	16.1	13.5	6.9	6.3	8.5

Balance Sheet

Abridged

Understanding Balance Sheet

Lotus Eye Hospital And Institute Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	R 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	IR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	4.03	7.49	6.62	5.67	5.55	6.77	8.09	6.59	10.70	13.60	12.86	14.71	14.02	11.57	11.37
Long-Term Investments	-	-	-	-	5.14	5.78	6.52	-	-	-	-	0.95	-	2.39	2.55
Property Plant & Equipment - Net	47.71	45.37	47.23	47.26	43.57	41.77	42.58	44.23	42.45	40.37	43.95	44.07	48.65	53.94	65.68
Total Non-Current Assets	52.01	49.41	51.94	50.75	49.28	48.17	50.12	49.93	47.74	45.63	48.73	48.48	52.61	58.00	71.22
Total Assets	56.05	56.90	58.55	56.42	54.83	54.94	58.21	56.52	58.44	59.23	61.60	63.19	66.63	69.57	82.60
Total Current Liabilities	4.55	5.14	6.73	6.09	4.55	4.21	6.99	5.62	6.10	5.82	5.75	5.19	6.23	7.42	9.34
Long Term Debt	0.26	0.11	0.05	0.67	0.48	0.30	0.09	0.10	0.40	0.14	0.67	0.19	0.69	2.15	13.01
Total Non-Current Liabilities	0.58	0.43	0.46	0.94	0.79	0.67	0.59	0.78	1.09	0.71	1.24	0.42	0.99	2.15	13.12
Total Liabilities	5.14	5.57	7.19	7.03	5.34	4.88	7.58	6.40	7.19	6.53	6.99	5.61	7.22	9.57	22.46
Total Shareholders' Equity	50.91	51.33	51.36	49.38	49.48	50.05	50.64	50.12	51.26	52.70	54.61	57.58	59.41	60.00	60.14
Total Equity	50.91	51.33	51.36	49.38	49.48	50.05	50.64	50.12	51.26	52.70	54.61	57.58	59.41	60.00	60.14
Total Liabilities & Equity	56.05	56.90	58.55	56.42	54.83	54.94	58.21	56.52	58.44	59.23	61.60	63.19	66.63	69.57	82.60

Cash Flow

Abridged

Understanding Cash Flow Statement

Lotus Eye Hospital And Institute Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	R 2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	1.75	4.15	3.62	2.51	4.41	3.77	4.85	3.62	4.38	3.73	5.46	6.80	6.29	3.31	2.98
Working Capital - Increase/(Decrease)	0.59	-0.24	1.06	-0.10	-0.89	-0.50	1.22	1.19	1.27	-0.66	-0.74	-2.04	-0.21	-0.61	-0.57
Net CF from Operating Activities	2.34	3.91	4.68	2.42	3.52	3.27	6.06	4.81	5.64	3.07	4.72	4.76	6.08	2.70	2.42
Capital Expenditures - Net	3.37	1.41	5.33	4.75	1.10	1.42	4.20	4.69	1.43	0.12	4.67	3.09	5.57	4.79	13.03
Net CF from Investing Activities	-3.37	-1.41	-5.33	-4.75	-1.10	-1.42	-4.20	-4.69	-1.43	0.09	-4.37	-2.66	-5.13	-4.35	-12.58
Dividends Paid - Cash - Total	-	-	-	-	-	-	1.25	1.25	-	-	1.03	1.04	1.04	0.01	0.01
Debt - LT & ST - Issuance/(Retirement) - Total	0.17	-0.15	-0.81	1.86	-0.49	-0.18	-0.20	-0.09	0.21	-0.26	-0.41	-0.57	-2.26	-1.23	9.85
Net Cash Flow from Financing Activities	0.17	-0.15	-0.76	1.93	-0.45	-0.18	-1.45	-1.35	0.21	-0.26	-1.45	-1.61	-3.30	-1.24	9.84
Free Cash Flow to Equity	-0.86	2.35	-1.46	-0.48	1.92	1.66	1.66	0.03	4.42	2.68	-0.36	1.10	-1.75	-3.32	-0.77
Free Operating CF net dividend	-1.04	2.50	-0.65	-3.07	2.37	1.82	0.54	-1.13	3.22	2.59	-1.00	0.62	-0.60	-2.14	-10.64
Free Operating CF	-1.04	2.50	-0.65	-3.07	2.37	1.82	1.79	0.13	3.22	2.59	0.03	1.66	0.44	-2.13	-10.63

Business Segment Analysis

FY End:

Mar 24

Lotus Eye Hospital And Institute Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Healthcare activities (100.0%)₹ 5.64 Cr

Revenue / Sales

Healthcare activities (100.0%)₹ 48.21 Cr

Assets

Healthcare activities (100.0%)₹ 66.63 Cr

Operating Income

Healthcare activities (100.0%)₹ 2.80 Cr

Regional Segment Analysis

Lotus Eye Hospital And Institute Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Lotus Eye Hospital And Institute Ltd.

Historical Segment Analysis

Track how Lotus Eye Hospital And Institute Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2024 Mar 31
	2024 Mar 31
Healthcare activities	6

Frequently Asked Questions

What is the revenue of Lotus Eye Hospital And Institute Ltd.?

The latest trailing twelve month revenue of Lotus Eye Hospital And Institute Ltd. is ₹ 57.25 Cr, reflecting a 1-year growth of 14.08% and a 3-year CAGR of 6.25%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Lotus Eye Hospital And Institute Ltd.?

The latest trailing twelve month net profit (PAT) of Lotus Eye Hospital And Institute Ltd. is ₹ 0.15 Cr, with a 3-year earnings CAGR of -65.63%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Lotus Eye Hospital And Institute Ltd.?

The trailing twelve month EBITDA of Lotus Eye Hospital And Institute Ltd. is approximately ₹ 0.29 Cr (based on an operating margin of 0.50%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Lotus Eye Hospital And Institute Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Lotus Eye Hospital And Institute Ltd. is 0.08. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Lotus Eye Hospital And Institute Ltd.?

The debt-to-equity ratio of Lotus Eye Hospital And Institute Ltd. stands at 0.26. The interest coverage ratio is 0.23x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Lotus Eye Hospital And Institute Ltd.?

The estimated book value per share of Lotus Eye Hospital And Institute Ltd. is 28.92 (derived from a P/B ratio of 4.00 and market price of ₹ 115.56), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Lotus Eye Hospital And Institute Ltd.?

The trailing twelve month operating cash flow of Lotus Eye Hospital And Institute Ltd. is ₹ 2.42 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Lotus Eye Hospital And Institute Ltd. report consolidated or standalone financials?

Lotus Eye Hospital And Institute Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.